Cat. No. 3892
Chemical Name: 4,4'-(Carbonylbis(imino-3,1-phenylen
Biological ActivityP2Y11 agonist (pEC50 = 6.27). Exhibits selectivity for P2Y11 over a range of P2Y and P2X receptors.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Meis et al (2010) NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-γ,γ'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J.Pharmacol.Exp.Ther. 332 238. PMID: 19815812.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for NF 546 include:
Barragán-Iglesias et al (2014) Role of spinal P2Y6 and P2Y11 receptors in neuropathic pain in rats: possible involvement of glial cells. Mol Pain 10 29. PMID: 24886406.
Gao et al (2013) The role of P2Y(14) and other P2Y receptors in degranulation of human LAD2 mast cells. Sci Adv 9 31. PMID: 22825617.
Do you know of a great paper that uses NF 546 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: NF 546, supplier, NF546, p2y11, purinergic, receptors, agonists, Tocris Bioscience, Purinergic (P2Y) Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Selective GPR84 agonistIHR-Cy3
Potent fluorescent Smo antagonistRo 6842262
Potent LPA1 antagonistAMG 853
Potent dual CRTH2 and prostaglandin D2 (PGD2) receptor antagonistAM 4668
Potent FFA1 (GPR40) agonistCATPB
FFA2 antagonist/inverse agonistOleanolic acid
Selective GPBA receptor (TGR5) partial agonistPPTN hydrochloride
High affinity and selective P2Y14 antagonistItraconazole
SMO antagonist; acts at different binding site to cyclopamine (Cat No. 1623)SAR 216471 hydrochloride
Potent P2Y12 antagonist; orally available
March 18 - 22, 2017
Little Rock, ARK, USA